Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
Mar. 31, 2025	Mar. 31, 2024
Operating expenses
Research and development	$ 5,418,682	$ 6,401,279
General and administrative	4,363,004	2,173,115
Total operating expenses	9,781,686	8,574,394
Loss from operations	(9,781,686)	(8,574,394)
Other (expense) income
Interest expense	(1,397,076)	(1,503,697)
Interest income	633,093	919,984
Other income		8,843
Loss on foreign currency	(8,602)	(739)
Total other (expense), net	(772,585)	(575,609)
Loss before income tax	(10,554,271)	(9,150,003)
Income tax benefit (expense)	0	0
Net loss	$ (10,554,271)	$ (9,150,003)
Net loss per share attributable to common stockholders, basic	$ (0.03)	$ (0.03)
Net loss per share attributable to common stockholders, diluted	$ (0.03)	$ (0.03)
Weighted-average number of common shares outstanding, basic	372,541,173	307,423,873
Weighted-average number of common shares outstanding, diluted	372,541,173	307,423,873

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.